Ascendis Pharma A/S

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
—
Employees—
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
—
Employees—

ASND Key Statistics

Market cap
17.70B
Market cap17.70B
Price-Earnings ratio
16.60
Price-Earnings ratio16.60
Dividend yield
—
Dividend yield—
Average volume
827.09K
Average volume827.09K
High today
$272.96
High today$272.96
Low today
$267.64
Low today$267.64
Open price
$269.02
Open price$269.02
Volume
405.82K
Volume405.82K
52 Week high
$282.15
52 Week high$282.15
52 Week low
$188.08
52 Week low$188.08

Stock Snapshot

As of today, Ascendis Pharma A/S(ASND) shares are valued at $269.87. The company's market cap stands at 17.7B, with a P/E ratio of 16.60.

On 2026-11-18, Ascendis Pharma A/S(ASND) stock traded between a low of $267.64 and a high of $272.96. Shares are currently priced at $269.87, which is +0.8% above the low and -1.1% below the high.

Ascendis Pharma A/S(ASND) shares are trading with a volume of 405.82K, against a daily average of 827.09K.

During the past year, Ascendis Pharma A/S(ASND) stock moved between $188.08 at its lowest and $282.15 at its peak.

During the past year, Ascendis Pharma A/S(ASND) stock moved between $188.08 at its lowest and $282.15 at its peak.

ASND News

Investor's Business Daily 23h
Dow Plunges 900 Points On Salesforce Carnage: Paycom, Ascendis, TGTX In Focus - Investor's Business Daily

...

Dow Plunges 900 Points On Salesforce Carnage: Paycom, Ascendis, TGTX In Focus - Investor's Business Daily
TipRanks 2d
Ascendis Pharma price target raised to $341 from $329 at Barclays

Barclays raised the firm’s price target on Ascendis Pharma (ASND) to $341 from $329 and keeps an Overweight rating on the shares. The firm views the company’s Q...

TipRanks 6d
Ascendis Pharma Grants 28,030 Employee Warrants

An update from Ascendis Pharma ( (ASND) ) is now available. Ascendis Pharma A/S is a pharmaceutical company focused on developing, manufacturing and selling me...

Analyst ratings

95%

of 22 ratings
Buy
95.5%
Hold
4.5%
Sell
0%

People also own

Based on the portfolios of people who own ASND. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.